Search | Clinical Trials Finder

Conditions: Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: cyclophosphamide, fludarabine phosphate, Aldesleukin, ALVAC gp100 Vaccine, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Contrast Induced Nephropathy
Interventions: Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate; Other · Drug
Lead sponsor: The Western Pennsylvania Hospital; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obsessive-Compulsive Disorder, Body Dysmorphic Disorders, Illness Anxiety Disorder
Interventions: Caloric Vestibular Stimulation; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Obinutuzumab, Bendamustine, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 15
States / cities: Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Ischemic Stroke
Interventions: Acetylcysteine, Dextrose in Water; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Torrance, California

Conditions: Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Stroke
Interventions: Conivaptan; Drug
Lead sponsor: Jesse Corry; Other
Eligibility: 19 Years to 79 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Obesity
Interventions: Intralipid Infusion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cerebral Vasospasm
Interventions: Nicardipine, Verapamil, Nicardipine + Verapamil + Nitroglycerin; Drug
Lead sponsor: Peng Roc Chen, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 5
States / cities: New Haven, Connecticut • Manhasset, New York • Winston-Salem, North Carolina + 2 more

Conditions: Ewing's Sarcoma, Rhabdomyosarcoma
Interventions: therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 35 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: Recombinant ADAMTS13; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Dublin, Ohio • Portland, Oregon • Houston, Texas

Conditions: Gastric Cancer, Pancreatic Cancer
Interventions: Diagnostic peritoneal lavage; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more

Conditions: Obesity, Childhood
Interventions: Pilot Intervention to reduce SSB consumption in children and families; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Year and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Kidney Cancer, Prostate Cancer
Interventions: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Acute Hypoxemic Respiratory Failure
Interventions: L-Citrulline, Placebo; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Metastatic Cancer
Interventions: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT); Biological · Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
Interventions: Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa; Other · Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Melanoma, Unresectable Melanoma
Interventions: Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI); Drug · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 66 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain, Colorectal Adenomas, Colorectal Cancer
Interventions: Air Insufflation method., CO2 insufflation, Water Immersion/CO2, Water Exchange/CO2, Water Immersion/AI, Water Exchange/AI; Other
Lead sponsor: Presidio Ospedaliero Santa Barbara; Other
Eligibility: 18 Years to 85 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Capsule + Powder supplementation, stable tracer infusion; Dietary Supplement · Other
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years to 100 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: College Station, Texas

Search by objective public record fields.

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

Caloric Vestibular Stimulation for Modulation of Insight in Obsessive-Compulsive Spectrum Disorders

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Investigation of Sleep in the Intensive Care Unit

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

Neuroimmune Mechanisms in Obesity

The Intra-arterial Vasospasm Trial

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Intervention to Reduce Sugar-Sweetened Beverage (SSB) Consumption in Children and Families

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

Autonomic Nervous System and Chronic Fatigue Syndrome

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Comparison of Methods to Distend the Colon During Insertion: CO2, Air Insufflation, Water-aided Colonoscopy

Fish Oil and HMB Supplementation in COPD